As of June 10, 2025, AcelRx Pharmaceuticals Inc (ACRX) reports a EV/EBITDA of -0.06.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing AcelRx Pharmaceuticals Inc's EV/EBITDA to Peers
To better understand AcelRx Pharmaceuticals Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| AcelRx Pharmaceuticals Inc (ACRX) | -0.06 |
| Eli Lilly and Co (LLY) | 47.14 |
| Catalent Inc (CTLT) | 45.03 |
| Zoetis Inc (ZTS) | 20.30 |
| Rubicon Organics Inc (ROMJ.V) | 13.57 |
| Royalty Pharma PLC (RPRX) | 13.32 |
Compared to its competitors, AcelRx Pharmaceuticals Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.